Delphia (USA)’s ProQR Therapeutics PRQR Stock Holding History

Delphia (USA)’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,480	Closed	-$108K	–	383
2021 Q4	$108K	Buy	+13,480	New	+$103K	0.11%	250

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Delphia (USA)'s PRQR Position: Q1 2022 in Review

Delphia (USA) sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 13,480 shares — an estimated $108K sold.

Delphia (USA) first reported a position in PRQR in Q4 2021 and held it in 1 quarter. The position peaked at $108K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

Delphia (USA) reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
Delphia (USA) sold 13,480 ProQR Therapeutics shares in Q1 2022, an estimated $108K.
Delphia (USA) first reported a position in ProQR Therapeutics in Q4 2021 and held it in 1 quarter.
Delphia (USA)'s ProQR Therapeutics position peaked at $108K in Q4 2021.
58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Delphia (USA)'s 13F filing for Q1 2022, filed 16 May 2022.